Autolus Therapeutics (AUTL) vs Century Therapeutics (IPSC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Century Therapeutics (IPSC) has outperformed Autolus Therapeutics (AUTL) over the past year, gaining 137.8% versus a loss of 26.2%. Over five years, AUTL leads with a -85.5% price change compared with -93.2% for IPSC. Autolus Therapeutics is the larger company by market cap ($241.7 million vs $211.6 million), about 1.1 times the size, while Century Therapeutics is growing revenue faster (+1556.8% vs +644.9%).
Century Therapeutics converts more of its revenue into profit, with a net margin of -8.8% versus -381.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AUTL | IPSC |
|---|---|---|
| Share price | $0.9073 | $1.17 |
| Market cap | $241.65M | $211.56M |
| 1-day change | -7.38% | -11.74% |
| YTD return | -54.41% | +17.09% |
| 1-year return | -26.24% | +137.76% |
| 5-year return | -85.51% | -93.23% |
| EPS (TTM) | $-0.96 | $-0.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $75.39M | $109.16M |
| Revenue growth (YoY) | +644.94% | +1556.76% |
| Net income (latest FY) | $-287.53M | $-9.58M |
| Gross margin | -27.83% | — |
| Operating margin | -358.87% | -15.82% |
| Net margin | -381.40% | -8.78% |
| 52-week high | $2.58 | $3.04 |
| 52-week low | $0.896 | $0.48 |
| Distance from 52-week high | -64.83% | -61.68% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +821.42% | +307.73% |
| Average volume | 2.07M | 759.69K |
| Shares outstanding | 266.34M | 181.60M |
| Employees | 752 | 78 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IPSC has outperformed AUTL by 164.0 percentage points over the past year.
- Century Therapeutics is more profitable, keeping -8.8 cents of every revenue dollar as net income versus -381.4 cents for Autolus Therapeutics.
- Century Therapeutics grew revenue faster in its latest fiscal year (+1556.76% vs +644.94%).
About Autolus Therapeutics
AUTL stock →Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 752 employees
About Century Therapeutics
IPSC stock →Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 78 employees
AUTL vs IPSC FAQ
Which is bigger, Autolus Therapeutics or Century Therapeutics?
Autolus Therapeutics (AUTL) is larger, with a market capitalization of $241.65M compared with $211.56M for Century Therapeutics (IPSC).
Which stock has performed better over the past year, AUTL or IPSC?
IPSC returned +137.76% over the past 12 months, compared with -26.24% for AUTL (price return, excluding dividends). Past performance does not predict future results.
Are Autolus Therapeutics and Century Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.